Morgensztern, D., Cobo, M., Ponce Aix, S., Postmus, P., Lewanski, C., Bennouna, J., . . . Investigators, O. B. O. T. A. L. (2018). ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC). Wiley.
Παραπομπή σε μορφή Chicago (17η εκδ.)Morgensztern, D., et al. ABOUND.2L+: A Randomized Phase 2 Study of Nanoparticle Albumin‐bound Paclitaxel with or Without CC‐486 as Second‐line Treatment for Advanced Nonsquamous Non‐small Cell Lung Cancer (NSCLC). Wiley, 2018.
Παραπομπή σε μορφή MLA (9th εκδ.)Morgensztern, D., et al. ABOUND.2L+: A Randomized Phase 2 Study of Nanoparticle Albumin‐bound Paclitaxel with or Without CC‐486 as Second‐line Treatment for Advanced Nonsquamous Non‐small Cell Lung Cancer (NSCLC). Wiley, 2018.